PUBLIC COMPANY
saveTerSera Therapeutics LLC
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 5pipeline
5
marketed
3
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 23Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
- —Margetuximab Expanded Access Program
- —Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
- phase2Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
🐶 Hiring Signal
News
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketPTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sang…fiercebiotech · 4d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that